News
Stay up to date on topics that are important to Nurse Practitioners.
-
CDC Advises Moderately or Severely Immunocompromised Teens, Adults to Get Fourth COVID-19 Shot
The Centers for Disease Control and Prevention (CDC) advised that moderately or severely immunocompromised teens and adults receive…
-
New-Onset Bladder Symptoms in Discharged COVID Patients
Men and women who have been hospitalized with COVID-19 have reported new-onset severe genitourinary symptoms, including increased frequency,…
-
FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to Omicron Variant
The FDA revised the authorization for two monoclonal antibody treatments, bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab…
-
FDA Approves Remdesivir (Veklury) for Outpatient COVID-19 Treatment
The FDA has expanded the approved use of remdesivir (Veklury) to certain non-hospitalized adults and pediatric patients for…
-
FDA Formally Approves Moderna’s COVID-19 Vaccine
The FDA formally approved the second COVID-19 vaccine, Moderna’s COVID-19 vaccine, which will be marketed as Spikevax. Spikevax…
-
First Generic of Cyclosporine Ophthalmic Emulsion Eye Drops (Restasis) Approved for Dry Eye
The FDA approved the first generic version of cyclosporine ophthalmic emulsion 0.05% single-use vials (Restasis) to increase tear…
-
CDC Issues Simplified New Recommendations for Pneumococcal Vaccination in Adults
Updated pneumococcal vaccine recommendations for adults were issued by the Centers for Disease Control and Prevention, calling for…
-
Rivaroxaban (Xarelto) Approved for Pediatric Indication to Help Prevent, Treat Clots
The FDA approved two new pediatric indications for rivaroxaban (Xarelto), a factor Xa anticoagulant with multiple indications in…
-
New Medication Spray Approved for Seasonal Allergic Rhinitis
The FDA approved olopatadine hydrochloride/mometasone furoate (Ryaltris) nasal spray, a combination histamine-1(H1)-receptor inhibitor/corticosteroid, for the treatment of symptoms…
-
National NP Practitioner Residency & Fellowship Training Consortium Receives Federal Recognition as Accrediting Agency
The National Nurse Practitioner Residency & Fellowship Training Consortium received federal recognition as accrediting agency by the US…
-
CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population
Citing what is currently known about COVID-19 and the Omicron variant, the CDC is shortening the recommended time…
-
CDC Recommends Expanded Eligibility of COVID-19 Booster to Children 12 to 15 Years Old
The CDC endorsed the FDA’s Advisory Committee on Immunization Practices’ (ACIP) recommendation to expand eligibility of booster doses…
Trending
-
FDA Approved Semaglutide Injection to Reduce Risk of Serious Heart Problems in Overweight Adults
-
The Role of Pharmacogenomics in Precision Mental Healthcare
-
OTC COVID-19 Diagnostic Tests May Have an Extended Shelf Life
-
AANP Offers Resources to Help NPs Detect and Treat Ulcerative Colitis
-
Multistate Outbreak of Salmonella Linked to Cucumbers
-
5 Key Benefits of Getting a Second Certification as a Nurse Practitioner
-
8 Key Tips for Effective Communication During Pediatric ENT Exams
-
Normalizing Anxiety: How NPs Can Guide Patients to Make Healthier Choices
-
CDC Endorses Lowering Pneumococcal Vaccination Age from 65 to 50
-
FDA Proposes Ban on Over-the-Counter Oral Nasal Congestion Medication
-
Using Technology to Combat Drug-Drug Interactions
-
Building a Strong Professional Nursing Network as a New Nurse Practitioner
Join our email list
Get new course alerts, newsletters and more delivered directly to your inbox
By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.